Shots:

• BeiGene and Asieris collaborate to evaluate the safety and efficacy of APL-1202 + tislelizumab as neoadjuvant therapy in patients with MIBC. APL-1202 has been approved to treat patients with locally advanced or metastatic UC and high expression of PD-L1 who failed to receive platinum-based CT
• Asieris plans to submit INDs in China and the US for P- I/II clinical study and determine the RP2D (recommended P-II dose)
• APL-1202 is an orally reversible MetAP2 Inhibitor with anti-angiogenic- anti-tumor activities- currently in P- III clinical trials in China as monthx for the 1L treatment of non-muscle invasive for the 2L treatment of NMIBC

  Ref: PRNewswire | Image: BeiGene